Actively Recruiting
Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA
Led by Kafrelsheikh University · Updated on 2024-08-20
900
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Along with the current clinical trial, the efficacy and safety of ticagrelor and aspirin administered within the first 24 hours of first-ever ischemic stroke compared to cilostazol and aspirin were assessed through NIHSS, mRS, and possible adverse effects.
CONDITIONS
Official Title
Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 75 years
- First-ever acute minor ischemic stroke or transient ischemic attack (TIA)
- Received antiplatelet treatment within 24 hours of stroke onset
- Not eligible for rt-PA treatment
You will not qualify if you...
- Not followed up for 90 days after enrollment
- NIHSS score greater than 4
- History of persistent or recurrent central nervous system diseases like epilepsy, meningioma, multiple sclerosis, or residual neurological deficits from head trauma
- Clinical seizures at stroke onset
- Symptoms of major organ failure or active cancer
- Acute myocardial infarction within the previous six weeks
- Use of warfarin, regular ticagrelor within the week before admission, or chemotherapy in the last year
- Active peptic ulcers, gastrointestinal surgery, or bleeding history within the last year
- Major surgery within the last three months
- Known allergy to study drugs
- INR > 1.4 or PT > 18
- Blood glucose less than 50 or greater than 400 mg/dL
- Blood pressure less than 90/60 or greater than 185/110 mmHg on admission
- Platelet count less than 100,000
- Pregnant or lactating
- Stroke due to venous thrombosis, wake-up stroke, or stroke following cardiac arrest or severe low blood pressure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kafr Elsheikh University Hospital
Kafr ash Shaykh, Egypt, 33155
Actively Recruiting
Research Team
M
mohamed G Zeinhom, MD
CONTACT
S
sherihan R. ahmed, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here